抗体名:Anti-Human TREM2 Antibody (al002)(流式抗体) 亚型:IgG1, kappa 浓度:1 mg/ml % 是否单克隆:是 靶点:TREM2 免疫原:Mouse 宿主:Mouse 用途:仅用于科研 保质期:1 year 应用范围:FCM 产地:France 标记物:Unconjugate 品牌:AntibodySystem
ChemicalBook 致力于为化学行业用户提供抗 HUMAN TREM2 抗体 (AL002) 单克隆抗体的性质、化学式、分子式、比重、密度,同时也包括抗 HUMAN TREM2 抗体 (AL002) 单克隆抗体的沸点、熔点、MSDS、用途、作用、毒性、价格、生产厂家、用途、上游原料、下游产品等信息。
Signaling by TREM2, an innate immune receptor expressed by microglia, is thought to enhance phagocytosis of amyloid beta (A尾) and other damaged proteins, promote microglial proliferation, migration, and survival, and regulate inflammatory signaling. Thus, TREM2 activation has potential to alter the...
Research Grade Anti-Human TREM2 Antibody (al002) 更多供应商普健生物(武汉)科技有限公司 联系电话: 027-87008169 17762441161 产品介绍: 英文名称:Research Grade Anti-Human TREM2 Antibody (al002) 纯度:>95% 包装信息:100ug 备注:科研级基本信息 中文名称 Research Grade Anti-Human TREM2 Antibody (al...
基本信息 药品名称 AL002 药品类别 创新药; 生物; 抗体 靶点 triggering receptor expressed on myeloid cells 2 (TREM2) 作用机制 anti-TREM2单抗 药品简介 -- 研发机构 Alector ;AbbVie 无权益 最高研发阶段 全球: II期临床 中国: 临床前 审评审批类型 -- 外置链接 -- 了解药物更多情报 登录...
TREM2 is a transmembrane receptor expressed on a subset of innate immune cells and selectively on microglia, which constitute the brain’s immune system. Reduction of TREM2 functionality may lead to Alzheimer's disease and other forms of dementia. AL002 counteracts this decrea...
AL002是一种在研的人源化单克隆抗体(mAb),它能与骨髓细胞2(TREM2)上表达的触发受体结合。TREM2是一种感知大脑病理变化的关键小胶质细胞膜受体,而AL002正是临床试验中最先进的TREM2激动剂候选产品。 研究采用了长达96周的随机治疗设计,所有患者都按照指定的治疗方案接受治疗,直到最后一名患者完成48周的治疗。这样...
Variants of the gene triggering receptor expressed on myeloid cells-2 (TREM2) increase the risk of Alzheimer’s disease (AD) and other neurodegenerative disorders. Signaling by TREM2, an innate immune receptor expressed by microglia, is thought to enhanc
Triggering receptor expressed on myeloid cells ‐2 (TREM2) is a prominent Alzheimer's disease (AD) risk gene that is expressed by microglia in the brain; reduced function of TREM2 is associated with a 3‐fold increase in AD risk. AL002 is a humanized monoclonal IgG1 antibody. The ...
Objective: INVOKE-2 is a randomized, double-blind, dose-ranging, placebo-controlled study evaluating the efficacy and safety of AL002 in participants with early AD (NCT04592874).Background: Triggering receptor expressed on myeloid cells 2 (TREM2) is expressed in the brain predominantly by ...